Wildon Farwell
CIK 1847941 · Chief Medical Officer · last filed 2024-08-20
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
DYN price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
830 WINTER STREET, MA 02451
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| DYN | Chief Medical Officer | 143,222 | $16.05 | $2.30M | -$955.5K | 20 | 2024-08-20 |
Recent Filings · Page 2 of 3
30 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-03-11 | DYN | Notice (144) Officer · Planned Mar 11, 2024 Sold: Form 4 filed Mar 11, 2024 |
−1,585 | -$40.7K | EDGAR |
| 2024-03-11 | DYN | Sell (S)10b5-1 Plan adopted Jul 14, 2023 |
−9,921 | -$256.6K | EDGAR |
| 2024-03-07 | DYN | Notice (144) Officer · Planned Mar 7, 2024 · 10b5-1 plan Sold: Form 4 filed Mar 11, 2024 |
−2,090 | -$54.0K | EDGAR |
| 2024-02-28 | DYN | Notice (144) Officer · Planned Feb 28, 2024 · 10b5-1 plan Sold: Form 4 filed Feb 28, 2024 |
−407 | -$10.2K | EDGAR |
| 2024-02-28 | DYN | Sell (S)10b5-1 Plan adopted Jul 14, 2023 |
−407 | -$10.2K | EDGAR |
| 2024-02-14 | DYN | Sell (S)10b5-1 Plan adopted Jul 14, 2023 |
−5,493 | -$137.7K | EDGAR |
| 2024-02-12 | DYN | Notice (144) Officer · Planned Feb 12, 2024 · 10b5-1 plan Sold: Form 4 filed Feb 14, 2024 |
−5,493 | -$137.7K | EDGAR |
| 2024-01-26 | DYN | Sell (S)10b5-1 Plan adopted Jul 14, 2023 |
−100 | -$2.5K | EDGAR |
| 2023-12-12 | DYN | Sell (S)10b5-1 Plan adopted Jul 14, 2023 |
−2,666 | -$28.4K | EDGAR |
| 2023-11-16 | DYN | Grant (A) | +82,512 | $0 | EDGAR |
10b5-1: the filer ticked the box for trades made under a Rule 10b5-1 trading plan, which sets the sales (or buys) in advance, so they say less about the insider's view at the time than a discretionary trade. The plan's adoption date is shown when the filing's footnotes give it.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment, and an amended or cancelled notice is not listed. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes. Someone who is no longer an officer or director (or never was) files no Form 4, so for them a sale shows up only on a later notice, which lists the seller's sales from the 3 months before it. "No sale on file" means neither record shows one; a dash in Net $ means the value filed on the notice doesn't fit the stock's price (likely a typo).
Sales Reported Only on Form 144
1 sale · $84.6K| Sold | Symbol | Shares | Proceeds | Avg Price | Listed On |
|---|---|---|---|---|---|
| 2024-09-11 | DYN | 2,645 | $84.6K | $31.99 | 2024-11-18 |